Platinum-resistant ovarian cancer has poor outcomes and few targeted options, while folate receptor alpha is overexpressed in most cases. Elahere (mirvetuximab soravtansine) turned that into a treatment.
It delivers the maytansinoid DM4 into tumor cells to disrupt microtubules, making it the first folate receptor alpha-directed antibody-drug conjugate approved. The intravenous therapy treats FR-alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after prior systemic therapy.
Elahere’s accelerated approval converted to full approval in 2024 on confirmatory MIRASOL survival data, and companion FR-alpha testing shapes eligibility. Its ocular toxicity requires ophthalmic monitoring, and the asset was central to AbbVie’s acquisition of ImmunoGen.
